Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Withdrawn before enrolling
Conditions studied: Breast Cancer
In brief
The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment. The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients.
Key facts
- Study ID
- NCT01257932
- Run by
- University of California, Irvine
- People needed
- 0
- Starts
- 2010-12-01
- Expected to finish
- 2013-10-01
- Last updated by the study team
- 2022-11-01
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Female, 18 years of age or older, non pregnant or nursing.
- Diagnosis of breast cancer and will be receiving chemo therapy treatments
You may not qualify if…
- 18 years of age or younger, pregnant or nursing.
- Previous treatment including chemo therapy, radiation, surgery, and hormone therapy.
- Previous diagnosis with other form of cancer.
Where it is running
- Beckman Laser Institute — Irvine, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.